Barbara Barnes Rogers, CRNP, MN, AOCN, ANP-BC - An Oncology Nurse MasterClass on Oral Therapy in B-Cell Malignancies: Insights on Evidence, Practical Strategies, and the Nurse-Patient Partnership

Go online to PeerView.com/TTY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent developments in B-cell lymphoma have increased the availability of novel, orally administered therapies. Nurse professionals managing patients with B-cell cancers play a central role in caring for patients who are eligible for treatment with oral therapeutics, including BTK, PI3K, and BCL-2 inhibitors, and immunomodulating agents. In this activity, based on a recent live symposium held at the ONS 44th Annual Congress, an expert nurse faculty panel offers an in-depth look at the integration of novel, orally administered therapies in the B-cell cancer setting and the therapeutic applications of these agents, as well as the practical issues that are central to oncology nursing practice. Upon completion of this activity, participants will be able to: Cite updated evidence about the use of novel, orally administered agent classes in B-cell cancers, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, and other oral therapies, Develop treatment plans in consultation with a wider oncology management team for patients with B-cell lymphoma who are candidates for oral therapies, Educate patients about practical issues surrounding the use of oral therapies for CLL, MCL, and FL, including adherence, safety, and therapeutic expectations, Manage dosing, adherence, and safety considerations in patients with B-cell lymphoma receiving oral agents as part of their therapy.